echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The heavy sales model of pharmaceutical companies has changed, and the sales expenses of 5 pharmaceutical companies in the first half of the year have dropped by more than 30% year-on-year.

    The heavy sales model of pharmaceutical companies has changed, and the sales expenses of 5 pharmaceutical companies in the first half of the year have dropped by more than 30% year-on-year.

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    With the promotion of the normalization of collection and procurement, the sales model of pharmaceutical companies has also changed
    .
    From the data of listed pharmaceutical companies that have disclosed their semi-annual reports in 2022, it can be seen that the mode of heavy sales in the past of many pharmaceutical companies has changed, and the sales cost has been greatly reduced
    .
    Among them, China Traditional Chinese Medicine, Yingke Medical, Ruikang Pharmaceutical, North China Pharmaceutical, Hengrui, these 5 pharmaceutical companies, although the sales costs in the first half of the year were more than 100 million yuan, but the year-on-year decline has exceeded 30%.
     

    Chinese traditional Chinese medicine: 43.
    6% reduction
     
    Chinese traditional Chinese medicine: 43.
    6% reduction
    The sales expenses of Chinese medicines in the first half of the year were 1.
    72 billion yuan, down 1.
    33 billion yuan or 43.
    6%
    from 3.
    04 billion yuan in the same period last year.

     

    Yingke Medical: 42.
    9% reduction
     
    Yingke Medical: 42.
    9% reduction
    Yingke Medical's sales expenses in the first half of the year reached 100 million yuan, a decrease of 42.
    9%
    compared with 180 million yuan in the same period last year.

     

    It is understood that the glove industry where Yingke Medical is located is fiercely competitive, and the company has said that in the face of intensified competition in the industry cycle adjustment stage, it will strive to further enhance its own strength from marketing, production, research and development, supply chain and other aspects, reduce costs and increase efficiency, and strive to increase market share and strengthen customer
    service.

     

    Ruikang Pharmaceutical: 41.
    9% reduction
     
    Ruikang Pharmaceutical: 41.
    9% reduction
    Ruikang Pharmaceutical's sales expenses in the first half of the year fell by 41.
    9% compared with the same period last year, from 920 million yuan in the same period last year to 540 million yuan
    in the first half of this year.

     

    In contrast, the company's R & D investment has increased significantly
    .
    In the first half of 2022, the company's R&D investment was 7.
    2023 million yuan, an increase of 116.
    98%
    year-on-year.

     

    North China Pharmaceutical: 30.
    9% reduction
     
    North China Pharmaceutical: 30.
    9% reduction
    The sales expenses of North China Pharmaceutical in the first half of the year were 840 million yuan, which was also significantly lower than the 1.
    22 billion yuan in the same period last year, a decrease of 30.
    9%.
     

    North China Pharmaceutical is mainly engaged in the research and development, production and sales of pharmaceutical products, and the company's products involve chemical drugs, biological drugs, health consumer goods, etc
    .
    In 2021, the company revealed at the 2020 annual performance briefing that in accordance with the principle of "clinical necessity, exact efficacy, and shortage of supply", it will increase investment in the research and development of innovative drugs, focus on the development of biological drugs based on monoclonal antibodies and chemical drugs based on innovative drugs, clinically urgently needed generic drugs, complex raw materials and preparations, and simultaneously accelerate product research
    in the field of antivirals.

     

    Not long ago, the company asked investors on the interactive platform" "Has the company's investment in research and development of new products increased compared with previous years?" The reply to this question said that the company's R & D investment in 2021 totaled 505 million yuan, an increase of 36 million yuan
    over 2020.

     

    Hengrui: 30% reduction
     
    Hengrui: 30% reduction
    As a "pharmaceutical brother", Hengrui accelerated its transformation and upgrading, with sales expenses of 3.
    27 billion yuan in the first half of the year, compared with 4.
    67 billion yuan in the same period last year, a drop of 30%.
     

    The report disclosed that in the first half of the year, Hengrui's sales staff decreased by more than 2,300 people
    .
    In recent years, Hengrui has actively reduced its sales staff, and in 2021, it will be reduced from 17,138 at the beginning of the year to 13,208, and the number of optimized sales personnel has reached 3,930
    .

     

    While cutting sales expenses and laying off sales personnel, Hengrui's R&D investment has been increasing
    .
    In the first half of 2022, the cumulative R&D investment reached 2.
    9 billion yuan, an increase of 12% year-on-year, and the proportion of R&D investment in sales revenue increased to 28% year-on-year, of which the cost-based R&D investment was 2.
    1 billion yuan, and the proportion of R&D expenses in sales revenue increased to 21%
    year-on-year.

     

    Under the continuous investment in research and development, the company has achieved great
    innovation results.
    Since 2022, Hengrui Pharmaceutical has approved two new drugs (including new indications), including the first domestic AR inhibitor revirutamine tablets approved in China, and the second indication obtained by pirrolinib for the neoadjuvant treatment
    of patients with HER2-positive early or locally advanced breast cancer.
    In addition, a total of 9 varieties have been approved for production and regarded as overrated, and 6 are the first to imitate; 4 varieties passed the consistency evaluation, and 3 won the first
    .
    According to the data of the Intranet, hengrui has been evaluated/treated as 60 varieties, of which 31 are the first to
    be evaluated.

     

    Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
    to any person.

     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.